Oct 2 -
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
It was published on October 2, 2026 on Semasocial.
It was written by CNBC on Semasocial.
News Source
CNBC is the world leader in business news and real-time financial market coverage. Find fast, actionable information.
Comment